Results 221 to 230 of about 57,115 (246)

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study

Annals of Oncology, 2009
C Louvet, G Lledo, A Figer
exaly  

Irinotecan

Reactions Weekly, 2008
openaire   +1 more source

Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study

Annals of Oncology, 2007
David Cunningham, Tamás Hickish, Richard H Osborne   +2 more
exaly  

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

European Journal of Cancer, 2014
Toshikazu Moriwaki, Norisuke Nakayama, Mizutomo Azuma   +2 more
exaly  

Irinotecan

Reactions Weekly
openaire   +2 more sources

Clinical and pharmacogenetic factors associated with irinotecan toxicity

Cancer Treatment Reviews, 2008
Hans Gelderblom, Henk-Jan Guchelaar
exaly  

IRINOTECAN PREPARATION

2005
YOSHINO KEISUKE, NOZAWA SHIGENORI, ISOZAKI MASASHI, SAWADA SEIGO, KATO IKUO, MATSUZAKI TAKESHI   +5 more
openaire   +2 more sources

Irinotecan

Reactions Weekly, 2022
openaire   +1 more source

Irinotecan

Reactions Weekly, 2015
openaire   +2 more sources

Irinotecan

Reactions Weekly, 2004
openaire   +2 more sources